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Abstract
To identify the clinical and pharmacological risk factors associated with tacrolimus
pharmacodynamics for acute graft-versus-host disease (aGVHD) in pediatric patients
receiving allogeneic hematopoietic stem cell transplantation (HSCT) from a matched
related donor. A retrospective cohort single center chart review study was conducted
with pediatric patients who received tacrolimus prophylaxis after allogeneic HSCT
between January 1, 2017, and December 31, 2019. Potential risk factors were tested
separately between aGVHD and non-aGVHD cohorts and were further analyzed in a
logistic regression model with backward elimination and a partial least squares discriminant analysis. Thirty-three patient cases were included in our study and 52%
(17/33) developed aGVHD while on tacrolimus prophylaxis. When tested independently, donor age and sibling versus parent donor/recipient relation were shown to
be statistically significant between aGVHD and non-aGVHD patients (p < 0.005).
Pharmacological factors associated with tacrolimus treatment failed to demonstrate
a significant impact on patient’s risk of aGVHD. Using a best fit logistic regression
model that tested all the variables together, donor age was the only significant variable predicting patient’s risk of aGVHD (p < 0.01). Donor relationship and donor
age were unable to be evaluated separately and are therefore confounding variables.
Among pediatric patients receiving allogeneic HSCT, aGVHD risk is significantly
decreased by either sibling donor and/or younger donors. Although no conclusions
were drawn on the effect of tacrolimus therapy (p = 0.08), results warrant additional
research with a larger sample size to evaluate the accuracy of monitoring tacrolimus
serum trough levels.

Abbreviations: aGVHD, acute graft-versus-host disease; AUC, area under the curve; CI, confidence interval; GVHD, graft-versus-host disease; DF, degrees
of freedom; HLA, human leukocyte antigen; HSCT, hematopoietic stem cell transplant; IV, intravenous; NIOSH, National Institute for Occupational Safety
and Health; PK, pharmacokinetic; PO, oral; RR, relative risk.
Phan and Chavan equally contributed to this study.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium,
provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
© 2021 The Authors. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of the American Society for Clinical Pharmacology and Therapeutics.
Clin Transl Sci. 2021;00:1–11.		
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Study Highlights

WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
WHAT QUESTION DID THIS STUDY ADDRESS?
Donor-related clinical factors play a large role in acute graft-versus-host disease
(aGVHD) development. Accounting for these factors while examining the pharmacological properties of tacrolimus is understudied in the pediatric setting.
WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?
This study investigated clinical and pharmacological risk factors that may affect
a pediatric hematopoietic transplant patient’s risk of aGVHD while on tacrolimus
therapy.
HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR
TRANSLATIONAL SCIENCE?
This study (1) is consistent with other studies in that sibling donors have a lower risk
of aGVHD than parent donors, and (2) provides exploratory data to guide future studies that examine the pediatric patient population.
Given the significant interpatient pharmacokinetic (PK) variability, our results suggest that monitoring other PK parameters, such as the area under the curve (AUC) in
addition to measuring trough levels reduce aGVHD risk in children.

I N T RO D U C T ION
Hematopoietic stem cell transplantation (HSCT) is typically
reserved for life-threatening diseases, such as relapsed acute
lymphoblastic leukemia and acute myeloblastic leukemia,
due to severe and life-threatening complications associated
with the procedure.1 Patients who undergo allogeneic HSCT
are at significant risk of graft-versus-host-disease (GVHD), a
debilitating condition where the patient’s immune system reacts to the donor’s cells and triggers an inflammatory cascade
that ultimately results in tissue damage and organ injury.
GVHD can present acutely or chronically and incidences of
GVHD in pediatric patients have been reported to be between
30% and 50%, varying by the type of transplant and the recipient’s relationship to the donor.2 Conditioning the patient
to have a successful engraftment while minimizing the risk
of developing GVHD is a delicate balance that remains challenging in current clinical practice.
Tacrolimus is a calcineurin inhibitor commonly used for
the prevention of acute GVHD (aGVHD), defined as GVHD
that occurs within 100 days post-transplant.3 To date, there
are very limited studies examining the pharmacokinetic
(PK) profile of tacrolimus in children post solid organ transplant.4,5 These PK studies have demonstrated significant
interpatient variability in drug exposure. The oral bioavailability of tacrolimus in children ranges even more widely
from 5% to 93%, with a mean bioavailability of 25% in patients who have undergone solid organ transplantation.6 Of
note, pediatric patients who undergo transplantation appear
to eliminate tacrolimus more rapidly than adult patients who
undergo transplantation. In patients undergoing HSCT, the
nonlinear PK model of tacrolimus is further complicated by

altered hepatic and renal function, and other severe complications, such as sinusoidal obstructive syndrome, that occur
after transplantation.
Tacrolimus has a narrow therapeutic index requiring
close monitoring of its trough levels.7,8 In adult patients
who undergo transplant, tacrolimus levels are typically
maintained between 10 and 20 ng/ml.8 However, the
target levels of tacrolimus in pediatric patients are not
conclusive and vary in practice among different institutions.9,10 Given the limited information collected from patient studies, finding a reliable predictive model to guide
patient care and clinical practice has been challenging.10
Additional challenges include being able to swiftly reach
a safe therapeutic serum level using an intravenous formulation and maintaining the target serum levels when
switching to oral administration, both of which are impacted by the metabolic variability among patients because tacrolimus is extensively metabolized primarily by
the hepatic P450 enzymes, such as CYP3A.11 Identifying
an appropriate dosing method, optimal target serum levels, and time to reach those levels may improve patient
outcomes, as suggested by Offer et al.10 Ultimately, more
studies are warranted to evaluate the use of tacrolimus in
pediatric patients with HSCT and to determine its clinical outcomes, such as patient’s risk of developing GVHD
post-transplantation.
Previous studies examining risk factors for developing
aGVHD have determined that one of the most important
factors is human leukocyte antigen (HLA) disparity, where
matched grafts have lower rates of aGVHD than HLA-
mismatched grafts.2 Other factors that may increase the likelihood of developing GVHD—acute and chronic—include
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donor age, sex mismatch, and the myeloablative regimen
used. Although these risk factors have been largely examined in the adult setting, only a few studies examined these
trends in children. Identifying the interaction between these
risk factors and tacrolimus use on the likelihood of developing aGVHD in pediatric patients with HSCT is understudied and prompts additional research. Therefore, the purpose
of this study is to examine the effect of tacrolimus levels on
developing aGVHD in pediatric patients with HSCT. The
dose of tacrolimus, the number of days it takes to reach
target levels, and other patient clinical and demographic
features have been evaluated as potential risk factors to determine their associations with the likelihood of developing
aGVHD.

ME T H O D S
Data collection
A retrospective, institutional review board-approved study
was conducted in patients who underwent HSCT and were
admitted to a children’s hospital, CHOC Children’s, from
January 1, 2017, until December 31, 2019. Patients with
HSCT who were younger than 26 years old and received
tacrolimus treatment for GVHD prophylaxis were included
in the study. Each transplant was examined as an individual
datapoint, meaning some patients were analyzed as multiple datapoints for each time they used tacrolimus as GVHD
prophylaxis for a transplant. Patients were excluded if they
died due to a complication separate from aGVHD.
The clinical information was obtained from each patient
via chart review, which includes age at time of transplant, gender, weight, diagnosis, starting dose, dose by weight, i.v. to
oral (p.o.) conversion, final p.o. to i.v. ratio (before tapering
off p.o.), aGVHD status, donor relationship, donor age, liver
toxicity (liver function tests and bilirubin levels), renal toxicity
(serum creatinine levels), and the HLA allele match in percentage. All trough levels measured within the first 100 days
post-transplant were collected and the following metrics were
calculated: the range of the tacrolimus trough levels obtained,
days to greater than 5 ng/ml on i.v. medication, days to greater
than 10 ng/ml on i.v., percent of serum trough levels less than
5 ng/ml, and percent of serum trough levels less than 10 ng/ml.
Due to the low representation of diagnoses, the patients were
further grouped into 4 categories in the statistical analysis
based on clinical relevance: group 1 (acute lymphoblastic leukemia), group 2 (acute myeloid leukemia and GATA2-related
deficiencies), group 3 (aplastic anemia, beta thalassemia intermedia, congenital thrombocytopenia, and sickle cell disease), and group 4 (Hodgkin’s lymphoma and hemophagocytic
lymphohistiocytosis).

|
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The donor relation was further divided into sibling, parent,
or unrelated. Hepatotoxicity was defined by an elevation of
serum transaminases greater than 5× normal upper level, or a
serum total bilirubin level greater than or equal to 2.0 mg/dL.12
Nephrotoxicity was defined as a doubling of serum creatinine
greater than baseline pretransplant value or a serum creatinine
greater than 2 mg/dL, which requires renal dose adjustment.13

Statistical analysis
Statistical analysis was done using “The R Project” for scientific computing version 3.6.2.14 A Power analysis for sample
size calculation was conducted using the data collected, followed by additional post hoc t-test power calculations using
the sample sizes in this study. To investigate variables associated with aGVHD, each variable was run separately comparing
the aGVHD group to the non-aGVHD group. A Welch t-test
was used for continuous variables unless normal distribution
assumptions were not met, in which case a Wilcoxon Mann–
Whitney was substituted. A Fisher’s exact test was used for
categorical variables.
Next, the variables were combined in a logistic regression. The aGVHD status was the dependent variable with
the above-mentioned clinical and demographic variables
as independent. Due to the large number of variables in
comparison to the number of subjects, an exhaustive algorithm, which investigated all possible combinations of independent variables, was used to determine the model with
the lowest Bayesian Information Criterion and the lowest
Akaike Information Criterion, followed by backward elimination to remove any nonsignificant variables from this
model.15 Due to computational limitations, the algorithm
is limited to 15 predictor variables. The 15 variables with
the strongest relationship to aGVHD status were used in
the algorithm, however, all remaining variables were added
during the process of backward elimination and tested for
inclusion in the final model. Primary results were based on
this logistic regression method and, therefore, p values were
not adjusted for the use of multiple statistical tests. Instead,
confidence intervals were included when possible. In order
to limit the influence of any confounding variables, a partial least squares discriminant analysis was conducted.16
This is a supervised learning method that uses the independent variables to best predict the outcome of the dependent
variable, in this case, aGVHD versus non-aGVHD. It is the
preferred method useful in cases of multicollinearity and
in data sets where there are many independent variables
compared with the number of subjects.17 Confounding
variables are often difficult to determine and can distort the
results. In our study, we used multiple statistical methods
to account for multicollinearity.
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This study was a single-
center retrospective study conducted at a 334-bed regional academic children’s hospital.
Approval for the study was received from the institutional
review board after expedited review. Pediatric patients who
received HSCT from January 1, 2017, until December 31,
2019, were identified. Records of 34 pediatric HSCT cases
were retrospectively reviewed. Thirty-
two individual patients were examined. Of the 32 patients, 2 patients underwent 2 transplants with tacrolimus prophylaxis, totaling 34
transplant cases examined in this study. One was excluded
due to exclusion criteria and a total of 33 transplant cases
were included in the final analysis.
Our study showed that 52% (17/33) of transplant cases
developed aGVHD while on tacrolimus prophylaxis treatment (Table 1). The average donor age was 14 years old and
15 years old for non-aGVHD and aGVHD patients, respectively (p > 0.05). Overall, 64% of transplant cases were with
male patients (Table 1). On average, patient weight was 58 kg
and 59 kg for aGVHD and non-aGVHD patients, respectively
(Table 2). Average patient body weight was also not significant when independently testing for aGVHD risk. Seventy-
three percent of the transplants were White patients, with 6%
being Asian and 21% identifying as “other.” Transplants also
predominantly used tacrolimus in combination with cyclophosphamide on day 3 and 4 post-transplant and mycophenolate on day 5 for aGVHD prophylaxis, with only 9% using
a different tacrolimus combination regimen. These patients
who received a different regimen were those diagnosed with
aplastic anemia (AA), whereas all four AA transplants received different regimens. Two out of the 34 transplants experienced aGVHD, failed tacrolimus therapy, and switched
to sirolimus (Table 1).
Thirty of 33 donors were haploidentical. The percentage of
HLA allele match between the donor and recipients were 58.3%
and 60.8% on average, respectively, in non-aGVHD and aGVHD
patients. Of note, the average age of donors in the aGVHD group
was 37.5 years old, much higher compared with that of non-
aGVHD patients (20.5 years old, p < 0.005; Table 2).

tacrolimus treatment, such as days to reach target levels (5 or
10 ng/ml), number of readings below target levels, average
trough levels, range of trough levels, and initial/final p.o.:i.v.
conversion ratios, did not exhibit statistical significance between the aGVHD and non-aGVHD cohorts (p > 0.05).
For patients who developed aGVHD, the average starting
i.v. dose by weight was 0.02 mg/kg (SD = 0.008), which is
a standardized practice with rounding-up to the nearest tenth
per protocol. When the patients were stabilized and able to
take p.o. medication, i.v. tacrolimus was then transitioned to
oral administration. The initial i.v. to p.o. conversion averaged
1:2.9 and 1:2.7, in aGVHD and non-aGVHD patients, respectively (p > 0.05 by t-test). The oral dose of tacrolimus was
then adjusted based on serum trough levels detected. The final
oral dosing of tacrolimus for maintenance before tapering off
was ~ 2.5-fold the initial i.v. dose on average in patients with
aGVHD, whereas such ratio was much higher in non-aGVHD
patients (4.7-fold). Given the limited patients, however, this
difference was not statistically significant (p > 0.05; Table 2).
In addition, the average trough levels of aGVHD and
non-aGVHD patients were 7.4 and 7.2 ng/ml, respectively,
with notable interpatient variabilities (Table 2). There was
a trend for the non-aGVHD cohort to have more subtherapeutic readings, where the average percentage of trough level
readings less than 5 ng/ml were 30.7% in the aGVHD cohort
and 35.5% in the non-aGVHD cohort. However, such difference did not reach statistical significance (p > 0.05). There
were 76.8% and 78.8% of trough readings below 10 ng/ml for
aGVHD and non-aGVHD cohorts, respectively (p > 0.05).
For patients who developed aGVHD, it took an average of
2.9 days to reach a target serum level of 5 ng/ml or higher,
which was shorter than those who did not develop aGVHD
(3.5 days). To reach a level above 10 ng/ml, it took an average of 6.1 days in patients with aGVHD and 8.6 days for the
non-aGVHD cohort (p > 0.05). Such difference (<3 days)
may not exhibit clinical significance in patient care practice.
Likewise, the categorical variables were tested individually for significance. No differences were identified in patient
gender, donor/recipient gender matching, presence of liver
toxicity, nor clinical diagnosis (Table 3). Among donor relationships, a significant difference was demonstrated between
sibling donors compared with parent donors (p < 0.005).

Individual variable analysis

Power analysis

The continuous variables were examined independently to
test for a significance in difference between the two cohorts—
aGVHD and non-aGVHD. Patient age did not reach significance, but donor age was significantly different between
these two cohorts, where older donor age was significantly
associated with an increased risk of aGVHD (p < 0.005;
Table 2). Pharmaceutical monitoring factors associated with

Using our collected data, a G-Power analysis for sample size
calculation was conducted.18 For example, in order to detect
a statistically significant difference between non-aGVHD
and aGVHD patients on the average recorded serum level
of tacrolimus (7.188 ng/ml ± 1.556 vs. 7.496 ng/ml ± 1.317,
respectively), a sample size of 788 was calculated to be sufficient to attain a power of 80% with a significant level of

Descriptive statistics

1

1

0

11

0

0

2

0

7

15.55 ± 7.35

8

3

5

6

Acute myeloid leukemia (n = 9)
GATA2-related deficiencies (n = 2)

Group 2

0

1

4

1

1

5

0

2

9.86 ± 6.39

3

4

0

7

Aplastic anemia (n = 4)
Beta thalassemia intermedia (n = 1)
Congenital thrombocytopenia (n = 1)
Sickle cell disease (n = 1)

Group 3

0

0

3

0

0

0

0

3

17.67 ± 2.08

0

3

2

1

Hodgkin’s lymphoma (n = 1)
Hemophagocytic lymphohistiocytosis (n = 2)

Group 4

T + MMF: tacrolimus + mycophenolate.

T + MMF + CPM: tacrolimus + mycophenolate + cyclophosphamide.

c

b

T + MTX: tacrolimus + methotrexate.

a

Abbreviations: aGVHD, acute graft-versus-host disease; CPM, cyclophosphamide; HSCT, hematopoietic stem cell transplantation; MMF, mycophenolate mofetil; MTX, methotrexate.

Failed tacrolimus therapy

+MTX

0

0

Other

Alone

2

Asian

12

10

White

Race

+MMF +CPMc

14.50 ± 5.75

Age (mean ± SD)

0

6

aGVHD

0

6

Non-aGVHD

+MMFb

5

Female

Tacrolimus regimen

7

Male

a

Acute lymphoblastic
leukemia (n = 12)

Group 1

Demographic characteristics of pediatric patients who underwent HSCT

Diagnosis

TABLE 1
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Comparison of clinical and demographic variables between aGVHD and non-aGVHD pediatric patients who underwent HSCT
NON-aGVHD
(n = 16)
means ± SDs

aGVHD (n = 17)
means ± SDs

Test statistic (95% CI)a

DF

Effect size
p value (d, 95% CI)c

Age

13.641 ± 6.711

14.676 ± 6.337

t = −0.455 (−5.68 to –3.61)

30.562

0.652

0.15
(−0.56 to –0.86)

Donor ageb

20.533 ± 11.288

37.500 ± 15.595

t = −3.486 (−26.949 to −6.984)

27.311

0.002

1.18
(0.41–1.95 )

Weight

58.425 ± 31.991

59.188 ± 28.702

t = −0.072 (−22.42 to –20.88)

30.127

0.943

0.02
(−0.69 to –0.73)

Dose by weight, mg/kg

0.020 ± 0.008

0.018 ± 0.004

U = 139

0.928

0.02
(−0.35 to –0.36)

Average recorded serum level

7.188 ± 1.556

7.496 ± 1.317

t = −0.612 (−1.337 to –0.721)

0.545

0.20
(−0.51 to –0.91)

Days to >5 ng/ml

3.562 ± 2.529

2.882 ± 1.409

U = 145.5

0.731

0.06
(−0.29 to –0.38)

Days to >10 ng/ml

8.688 ± 9.864

6.062 ± 5.651

U = 155.5

0.304

0.18
(−0.17 to –0.51)

35.518 ± 19.386

30.739 ± 16.941

t = 0.752 (−0.082 to –0.178)

0.458

0.25
(−0.46 to –0.96)

Percent of readings <10 ng/ml 78.832 ± 18.889

76.785 ± 12.066

U = 161.5

0.368

0.16
(−0.17 to –0.51)

0.697

0.14
(−0.58–0.85)

Percent of readings <5 ng/ml

29.484

29.853

Initial p.o. to i.v. conversion
ratio

2.705 ± 1.416

2.879 ± 0.963

t = −0.394 (−1.085 to –0.737)

24.667

Final p.o. to i.v. conversion
ratio

4.743 ± 4.394

2.583 ± 1.796

U = 141

0.244

0.21
(−0.13–0.53)

Percentage of allele match
58.333 ± 14.247
between donor and receipts,
%

60.784 ± 16.730

U = 126

0.697

−0.07
(−0.40 to –0.29)

Tacrolimus trough level range, 16.631 ± 6.465
ng/ml

15.200 ± 6.113

U = 156

0.482

0.13
(−0.25 to –0.46)

Bold indicates the statistical significant values.
Abbreviations: aGVHD, acute graft-versus-host disease; CI, confidence interval; DF, degree of freedom; HSCT, hematopoietic stem cell transplantation.
a

A Welch t-test was used for continuous variables unless normal distribution assumptions were not met in which case a Wilcoxon Mann–Whitney test was substituted.

b
c

This is confounded by whether the donor is a parent or a sibling.

A Cohen’s d was computed for comparisons using a t-test and an r statistic for comparisons using a Wilcoxon Mann–Whitney test.46–48

0.05. For the “percent of readings <5 ng/mL,” our calculated
sufficient sample size was 506 in order to detect statistically
significance with a power of 80%. However, to conduct a retrospective study with such a big sample size is challenging,
particularly for pediatric patients who received HSCT.
Further post hoc t-test power calculations with using the
sample sizes in this study indicate with an effect size d = 0.80
power is 0.60.18 The power is lowered when the distributions
are skewed, necessitating the use of the Wilcoxon Mann–
Whitney test. Effect sizes are shown in Table 2, indicating
areas that may warrant further study. However, in our study,
there is sufficient power to obtain significance with large effect sizes (26 subjects are needed to achieve 82% power with
an effect size of 1.18 using G-power), so the large effect size
and statistical significance of donor age merit attention despite our small sample size. In addition, we also gathered

information on the magnitude of effect on these other measures to help with future multi-center and prospective studies.

Logistic regression model
After the model selection process and backward elimination,
the only significant factor remaining in our model analysis was
donor age (p < 0.01; Table 4). When donor age was removed
from the model, donor relationship remained as a significant
variable associated with aGVHD risk (p < 0.005; Table 4). In
either of the reduced models, donor age or relationship, donor
gender match was the final variable removed from the model.
Applying a likelihood ratio test in either of the reduced models
demonstrated that donor gender match had p values of 0.06 and
0.07, when compared with the models without gender match.
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T A B L E 3 Statistical analysis of the
association of categorical variables with
risk of aGVHD in pediatric patients who
underwent HSCTa

|

RR (95% CI)

p value

Gender

1.048 (0.522–2.104)

1.0

Donor

Sibling: parents

3.569 (1.264 10.067)

0.00385

Sibling: unrelated

2.333 (0.422–12.911)

0.450

Parents: unrelated

0.654 (0.160–2.680)

0.468

Donor/recipient gender
matching

0.643 (0.340–1.214)

0.282

Hepatic toxicity

1.413 (0.610–3.271)

0.465

Diagnosis group

b

0.165

7

Bold indicates the statistical significant values.
Notes: The only variable that appears significantly different between the aGVHD groups is the donor relation.
Abbreviations: aGVHD, acute graft-versus-host disease; CI, confidence interval; HSCT, hematopoietic stem
cell transplantation; RR, relative risk.
a

Fisher’s Exact test.

b

Individual RR not included due to multiple comparisons and nonsignificant value.

T A B L E 4 Logistic regression model after backward elimination
using the best fit model: donor relation run with donor age removed
Variable

Odds
ratio

CI

Z-value

p value

Donor age

1.088

1.030–1.168

2.707

0.007

Donor relation:
parent-siblinga

0.084

0.013–0.412

−2.859

0.004

Donor relation:
parent-unrelated

0.308

0.010–8.973

−0.773

0.440

Bold indicates the statistical significant values.
Abbreviation: CI, confidence interval.
a

Significant when run separately from donor age.

To further confirm the importance of potential confounding factors included in our regression model, a partial least
squares discriminant analysis was conducted. The highest
variance was explained using a two-factor model as shown
in Figure 1. The first component explains 13% of the variance and adding the second component only yields an additional 4%. The largest factor loading of the first component
is the donor age, indicating that this variable had the highest
relative importance in discriminating between patients who
develop aGVHD from those that do not. The factor loading
for this variable was −0.64, whereas the next closest variable
was 0.36. This supports our findings that were demonstrated
by using the logistic regression model, suggesting that donor
age was associated with significantly higher risk of developing aGVHD in pediatric patients with HSCT. Notably such
risk of aGVHD post-HSCT was independent of the allele
matching between donor and recipient.
Our main statistical test was a single regression model attempting to predict aGVHD using multiple predictors. Secondary
to this approach, each variable was assessed separately in order
to examine its relationship to aGVHD and stimulate further research. The developed model is a type 1a prediction model, where

the predictive performance was directly evaluated using the same
study data.19 Effect sizes and confidence intervals were included
to further assess the cost and feasibility of such a study based on
the sample sizes needed. Because this investigation is exploratory
in nature, we did not correct for multiple testing. The inclusion of
confidence intervals allows other researchers to draw their own
conclusions regarding the strength of the findings.

DISCUSSION
Allogeneic HSCT is an important therapeutic option and a
potentially curative procedure for a variety of malignant and
nonmalignant severe conditions. Despite the advancement
in pharmacology and the development of less toxic preconditioning regimens, GVHD remains the most frequent and
serious complication following allogeneic HSCT, which
remarkably impacts a patient’s survival and quality of life.
Previous studies showed that 22% to 44% of patients who
underwent HSCT developed grades II to IV aGVHD post-
transplantation from HLA-
matched siblings even with
tacrolimus prophylaxis treatment.13,20 How to reduce the incidence of GVHD overall—acute and chronic—and its severity remains the biggest challenge for clinical professionals.21
This retrospective study aimed to determine the potential
confounding risk factors associated with aGVHD in pediatric patients who underwent HSCT using a logistic regression analysis and partial least squares discriminate analysis.
Many clinical and pharmacological risk factors have been
shown to be associated with development of aGVHD in pediatric transplant patients, such as patient age, total body
irradiation, diagnosis at transplantation, donor/recipient
gender, and graft source.2,22 A study compared potential
risk factors associated with aGVHD and chronic GVHD
in over 2900 adult and pediatric patients who received allogeneic hematopoietic cell transplantation and found that
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F I G U R E 1 Visualization of significant variables within the best fit model and the accounted variance. (a) The aGVHD status in relation to
donor age and relationship: each point is representative of a donor. Orange points represent donors associated with patients with aGVHD, whereas
blue points represent donors associated with non-aGVHD patients. (b) Two-factor model demonstrating the highest variances associated with the
development of aGVHD in pediatric patients with allogeneic HSCT: component 1 (X axis) explains 13% of the variance for increased aGVHD risk.
The addition of component 2 (Y axis) accounts for an additional 4% of the variance. aGVHD, acute graft-vs.-host disease; HSCT, hematopoietic
stem cell transplantation

recipient HLA mismatching and the use of unrelated donors
exhibited a greater risk of aGVHD.22 For pediatric patients,
limited studies showed that older donor age and female
donor sex were particularly associated with increased rate
of aGVHD.23,24
In our study, only two patients received transplantation
from unrelated donors; all the other donors were related,
being either parents or siblings of the recipient. Further analysis demonstrated that among the related donors, both the
donor relation and the donor’s age were significantly related
to the development of aGVHD. These two factors—donor’s
age and relation—could not be analyzed separately in our
study, because all but two of our patients were either siblings
or parents. However, both variables are independent of HLA
allele matching status and gender matching. The parent donors, ranging from 25 to 59 years old, exhibited a relatively
higher aGVHD risk of 3.5 times compared with that of sibling donors (2–24 years old). Our finding of an older donor’s
age being a significant predictive factor of aGVHD in pediatric patients with HSCT with related donor was consistent
with an early study reported by Mori’s et al.25
It is well-documented that tacrolimus exhibits significant
pharmacological interpatient and intrapatient variability.
Such variability necessitates the collection of serial trough
concentrations to ensure that the drug remains within the
targeted therapeutic range to minimize the risk of aGVHD.
The metabolism of tacrolimus is further complicated by
the developmental stages of pediatric patients,26 CYP3A5
genotype,11,27 race/ethnicity,28 concomitant CYP-
inducing
medications, such as antifungals, and dosing regimen.29
The clearance of tacrolimus has shown to be age-dependent,
with children younger than 5 years old exhibiting a higher

weight-normalized clearance compared with older children
and adults.30
In current practice, the drug monitoring of tacrolimus is
based on its serum trough levels and the dosage is adjusted to
maintain the target serum levels between 5 and 15 ng/ml. As
previously mentioned, target serum levels are varied among
different institutions and guidelines.8 Interpreting tacrolimus serum levels and the associated risk of toxicities, such
as nephrotoxicity, has been studied well.20 Yet, only a few
studies in children have evaluated the relationship between
the serum trough levels of tacrolimus and the occurrence of
aGVHD, and the relationship remains controversial and inconclusive. There were studies suggesting that a higher target
tacrolimus level post-transplant was associated with reduced
risk of aGVHD.25,31,32 The cutoff or target trough levels varied among different studies, ranging from 7 to 20 ng/ml in
children post-allogeneic bone marrow transplantation.8,10,31,33
One study demonstrated that every decrease of 1 ng/ml in tacrolimus mean concentrations over weeks 2–3 post-transplant
leads to an ~ 13% increased incidence of aGVHD.34 On the
contrary, certain reports failed in identifying a relationship
between the blood concentrations of tacrolimus and the occurrence of aGVHD in children.20
Another notable observation of our study is that we failed
to demonstrate a significant impact of the target trough levels of tacrolimus on the development of aGVHD, nor was it
affected by the time to reach target levels. The treatment and
monitoring plans after transplantation were standardized in
the study institution and implemented by oncology pharmacists, which minimized the potential discrepancies associated
with tacrolimus dosing and monitoring. In our retrospective
study, 17 (-%) patients who underwent HSCT on tacrolimus
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treatment experienced aGVHD, despite the fact that ~ 70%
of trough levels were above the therapeutic target of 5 ng/ml.
Neither the mean serum trough level nor the time to reach
target level (≥5 ng/ml or ≥10 ng/ml) was shown to be associated with the risk of aGVHD among our studied pediatric
patients.
Area under the concentration-time curve (AUC) is generally used as the PK exposure parameter after an oral administration, which is shown to be best associated with
clinical outcomes.29,35,36 Notably, PK studies demonstrated
that the trough levels of tacrolimus correlates poorly with
the AUC0–12,37 suggesting a calculated AUC based on two
measured serum levels may provide a more precise and cost-
effective model for tacrolimus monitoring. However, to the
best of our knowledge, very limited prospective studies have
been conducted in pediatric transplant recipients to determine the potential benefits of AUC0–12 monitoring compared
with trough level-guided pharmacotherapy. An earlier study
revealed that the AUC0–12 after the first oral dose of tacrolimus was significantly lower in heart transplantation recipients who experienced acute rejection compared with those
who did not.38
PK studies demonstrated distinct metabolic profiles
among patients, which may result in significant difference
in drug exposure.39,40 Simply monitoring trough levels may
limit its capacity to precisely guide and optimize the tacrolimus therapy. Most of the comparison studies of different
tacrolimus formulations utilized AUC instead of trough levels to compare the efficacy of tacrolimus.35,36 Consistently,
the final p.o. to i.v. ratio of tacrolimus was much higher in
non-aGVHD patients compared with that of the patients
who developed aGVHD (4.9-fold and 2.5-fold of i.v. dosing, respectively), yet, we failed to observe any significant
changes of the average trough levels between the two groups.
A prospective study to investigate the association between
tacrolimus AUC and clinical outcomes, such as incidence of
aGVHD and patient’s survival, is greatly warranted.
In general, patients with HSCT were initiated tacrolimus therapy as a continuous i.v. infusion. After the patient
reached the target level and was capable of oral intake, tacrolimus was then converted to p.o., which continued until
at least day +90 and was tapered off by day +180 post-
transplant. The pediatric dosage of tacrolimus is generally
individualized based on patient body weight, which is much
smaller compared with the adult dose. Current available
oral dosage forms are limited to capsule and tablet forms,
which are not feasible for pediatric patients, especially
younger children. As a general practice, many children’s
hospitals are compelled to extemporaneously compound
oral solutions using immediate-release capsules. Of note,
tacrolimus is a National Institute for Occupational Safety
and Health-listed hazardous drug requiring special handling when compounding extemporaneously.41 As such,
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there is an urgent need of developing an age-appropriate,
safe, and effective formulation of tacrolimus for pediatric
patients.
In addition, the prophylaxis efficacy of tacrolimus may
be affected by distinct combination regimens, such as sirolimus, mycophenolate, and methotrexate.42,43 In our study
institution, the most commonly used GVHD prophylaxis
regimen was the combination of tacrolimus, mycophenolate,
and cyclophosphamide (30/33, 91%), which minimized the
need to examine the potential effects of different regimens on
patient’s risk of aGVHD.
Importantly, in earlier studies of patients with HSCT, 34–
78% using tacrolimus, either alone or in combination, cumulatively developed nephrotoxicity during the first 100 days after
marrow transplantation.12,13 However, in our retrospective
study, no significant nephrotoxicity was identified. The overall lower incidence of nephrotoxicity in our study may be related to the lower levels of tacrolimus (5–15 ng/ml) that were
maintained in our study population and the low target level of
5 ng/ml as recommended by the institution. One study suggested that the risk of nephrotoxicity was markedly increased
when the mean trough level over 14 days was greater than
or equal to 20 ng/ml.20 Our patients rarely exceeded trough
levels greater than or equal to 20 ng/ml with pharmacist-led
drug therapy monitoring practice (<1% of all the documented
levels). In the event of greater than or equal to 20 ng/ml, tacrolimus doses were quickly reduced or placed on hold.
A potential limitation is the nature of a single-institution
retrospective cohort study, which restricts the number of eligible patients and reduces the power for statistical analysis.
Pediatric cancer incidences are generally lower than adults.
Approximately 0.61% of new cancer cases in the United
States in 2020 will be pediatric patients aged 0–14 years
old, and of that, 28% will be leukemia.44 There is also an
increasing rate of pediatric patients achieving remission; for
example, the 5-year survival rate for children with acute lymphoblastic leukemia has now greatly increased to about 90%
overall. HSCT is reserved for relapsed or refractory patients
who failed other treatments, so the total number of patients
meeting our study criteria will be much smaller compared
with other similar studies conducted in adult patients. That
explains why similar studies with pediatric patients are limited with patient sample size (22–
55 patients).9,30,45 Due
to the relatively small sample size and the large number of
predictors, this study should be considered exploratory. The
small sample size creates a higher risk of both type I and type
II errors. Type I errors could occur if our population was systematically different from the population. The possibility of
type II errors is increased as the power of this study makes it
difficult to detect moderate or small effect sizes, which may
be clinically significant. Based on the TRIPOD guidelines by
Collins et al., this study falls under the type 1a: development
only model, which suggests that our results could be improved
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with an enlarged patient sample size and a multicenter study
to validate and refine our predictive risk factor model.19 The
data generated from this study is critical for power analysis,
which will allow us to better estimate the adequate sample
size relative to the study goals and the possible variabilities
of the study, in order to optimize the study design.
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10.

CO NC LU S IO N
Our single-
institution retrospective cohort study demonstrated that the risk of aGVHD was significantly increased
with parent donors and/or donors older in age among pediatric patients receiving allogeneic HSCT from matched-related
donors. We failed to observe a significant decisive role of
pharmacological factors associated with tacrolimus treatment in a patient’s risk of aGVHD, although some studies
indicated that these factors may play a role in aGVHD.8,12
Further prospective studies in a larger, more racially diverse
cohort to investigate these finding are warranted.
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